CONNECT WITH US
HealthTech

HealthTech

Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?

Endpoints News logo

Published on

Add as a preferred source on Google
Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?

Be­yond the can­cer vac­cine, how did Mer­ck’s on­col­o­gy pipeline do at ES­MO?

MADRID — Much of the cov­er­age on Mer­ck at the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy con­gress cen­tered on its Mod­er­na-part­nered can­cer vac­cine tri­al. But the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Roche’s chang­ing plans show how MFN is com­pli­cat­ing Eu­ro­pean drug launch­es October 26, 2026

EGFR-mu­tant lung can­cer is an ADC bat­tle­ground, with Chi­na lead­ing the charge October 26, 2026

As­traZeneca's two-pill com­bo may ex­tend Tagris­so's life in lung can­cer October 25, 2026

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults

Mer­ck and Mod­er­na's can­cer vac­cine da­ta were 'a tri­umph of sci­ence.' And now, the work be­gins

Roche takes vic­to­ry lap with lung can­cer pil­l's win over Am­gen, Bris­tol My­ers

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.